614 results on '"Wiviott, Stephen D."'
Search Results
2. The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial
3. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
4. Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3
5. Abstract 14750: Performance of a Polygenic Risk Score for Coronary Artery Disease Across the Spectrum of ASCVD: An Analysis of 60k Patients From 6 TIMI Randomized Trials
6. Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
7. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
8. Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy.
9. Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial.
10. Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities
11. Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis
12. Abstract 14726: Serial Assessment of Cardiac Biomarkers and Risk of Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58
13. Abstract 12593: Type 2 Diabetes Mellitus Polygenic Score Predicts New Onset Diabetes in Patients With Established Atherosclerotic Cardiovascular Disease: A FOURIER Sub-Study
14. Abstract 10006: The Effect of Dapagliflozin on Hospital Admissions in Patients With Type 2 Diabetes: Post Hoc Analysis of the DECLARE-TIMI 58 Trial
15. Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial
16. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
17. The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
18. Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT
19. Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor
20. Causes of late mortality with dual antiplatelet therapy after coronary stents
21. Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61
22. Hepatic Fat Changes with Antisense Oligonucleotide Therapy Targeting ANGPTL3
23. Outcomes of Women Compared With Men After Non–ST-Segment Elevation Acute Coronary Syndromes
24. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
25. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
26. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
27. Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61.
28. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
29. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 inhibition in Patients with Type 2 Diabetes
30. Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non–ST-Segment–Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial
31. Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non–ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial)
32. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
33. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
34. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes
35. Abstract 16185: Biomarker-based Heart Failure Risk Stratification in Patients With Atherosclerotic Cardiovascular Disease: Observations From HPS-3/TIMI-55-REVEAL
36. Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58
37. Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58
38. Abstract 14799: Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial
39. Abstract 14769: Outcomes of a Smartphone-based Application With Live Health-coaching Post-percutaneous Coronary Intervention
40. Abstract 12923: Development of a Novel Biomarker-based Risk Score for Heart Failure in Patients With Diabetes
41. Response by Zelniker et al to Letter Regarding Article, “Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial”
42. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
43. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial
44. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial
45. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus
46. RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58
47. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE
48. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial
49. Use of Coronary Computed Tomographic Angiography Findings to Modify Statin and Aspirin Prescription in Patients With Acute Chest Pain
50. Response by Kato et al to Letter Regarding Article, “Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus”
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.